103 related articles for article (PubMed ID: 38867526)
1. 24 Factorial Design Formulation Optimization and In vitro Characterization of Desloratadine Nanosuspension Prepared Using Antisolvent Precipitation.
El-Sebaiy MT; Alyami MH; Alyami HS; Kamal MA; Eissa N; Balata G; El-Nahas H
Curr Drug Deliv; 2024 Jun; ():. PubMed ID: 38867526
[TBL] [Abstract][Full Text] [Related]
2. Study of Formulation and Process Variables for Optimization of Piroxicam Nanosuspension Using 3
Alhamhoom Y; Honmane SM; Hani U; Osmani RAM; Kandasamy G; Vasudevan R; Paramshetti S; R Dudhal R; K Kengar N; Charde MS
Polymers (Basel); 2023 Jan; 15(3):. PubMed ID: 36771784
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
4. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
5. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
[TBL] [Abstract][Full Text] [Related]
6. Formulation and Evaluation of Isradipine Nanosuspension and Exploring its Role as a Potential Anticancer Drug by Computational Approach.
Mohapatra PK; Srivastava R; Varshney KK; Babu SH
Anticancer Agents Med Chem; 2022; 22(10):1984-2001. PubMed ID: 34353274
[TBL] [Abstract][Full Text] [Related]
7. Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique.
Zu Y; Wu W; Zhao X; Li Y; Wang W; Zhong C; Zhang Y; Zhao X
Int J Pharm; 2014 Aug; 471(1-2):366-76. PubMed ID: 24882039
[TBL] [Abstract][Full Text] [Related]
8. Formulation and Characterization of Ursodeoxycholic Acid Nanosuspension Based on Bottom-Up Technology and Box-Behnken Design Optimization.
Boscolo O; Flor S; Salvo L; Dobrecky C; Höcht C; Tripodi V; Moretton M; Lucangioli S
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631251
[TBL] [Abstract][Full Text] [Related]
9.
Shariare MH; Altamimi MA; Marzan AL; Tabassum R; Jahan B; Reza HM; Rahman M; Ahsan GU; Kazi M
Saudi Pharm J; 2019 Jan; 27(1):96-105. PubMed ID: 30662312
[TBL] [Abstract][Full Text] [Related]
10. Development of a Resveratrol Nanosuspension Using the Antisolvent Precipitation Method without Solvent Removal, Based on a Quality by Design (QbD) Approach.
Kuk DH; Ha ES; Ha DH; Sim WY; Lee SK; Jeong JS; Kim JS; Baek IH; Park H; Choi DH; Yoo JW; Jeong SH; Hwang SJ; Kim MS
Pharmaceutics; 2019 Dec; 11(12):. PubMed ID: 31861173
[TBL] [Abstract][Full Text] [Related]
11. Design and Evaluation of Eudragit RS-100 Based Itraconazole Nanosuspension for Ophthalmic Application.
Pawar P; Duduskar A; Waydande S
Curr Drug Res Rev; 2021; 13(1):36-48. PubMed ID: 32990554
[TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of amorphous ezetimibe nanosuspensions intended for enhancement of oral bioavailability.
Thadkala K; Nanam PK; Rambabu B; Sailu C; Aukunuru J
Int J Pharm Investig; 2014 Jul; 4(3):131-7. PubMed ID: 25126526
[TBL] [Abstract][Full Text] [Related]
13. Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation.
Nakarani M; Misra AK; Patel JK; Vaghani SS
Daru; 2010; 18(2):84-90. PubMed ID: 22615599
[TBL] [Abstract][Full Text] [Related]
14. Development of novel polymer-stabilized diosmin nanosuspensions: in vitro appraisal and ex vivo permeation.
Freag MS; Elnaggar YS; Abdallah OY
Int J Pharm; 2013 Sep; 454(1):462-71. PubMed ID: 23830765
[TBL] [Abstract][Full Text] [Related]
15. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
16. Increased Oral Bioavailability of Piperine from an Optimized Piper nigrum Nanosuspension.
Zafar F; Jahan N; ; Bhatti HN
Planta Med; 2019 Feb; 85(3):249-257. PubMed ID: 30357764
[TBL] [Abstract][Full Text] [Related]
17. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
Karakucuk A; Celebi N; Teksin ZS
Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
[TBL] [Abstract][Full Text] [Related]
18. Enhancing Betulinic Acid Dissolution Rate and Improving Antitumor Activity via Nanosuspension Constructed by Anti-Solvent Technique.
Li S; Zhang J; Fang Y; Yi J; Lu Z; Chen Y; Guo B
Drug Des Devel Ther; 2020; 14():243-256. PubMed ID: 32021108
[TBL] [Abstract][Full Text] [Related]
19. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation.
Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N
Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.
Thakkar HP; Patel BV; Thakkar SP
J Pharm Bioallied Sci; 2011 Jul; 3(3):426-34. PubMed ID: 21966165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
